Business
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. “We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical de
About this update from Genelux Corporation
[{"type":"image","alt":"Genelux Corporation","displaySize":"","headline":null,"caption":"Genelux Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqbnzpB7NuWaPPuiKZD5BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea","width":300,"height":75}},"lazy":false},{"type":"image","alt":"Litten, Jason","displaySize":"","headline":null,"caption":"Litten, Jason","className":"","disableSlideshowImg":false,"size":{"original":{"width":4594,"height":4596,"url":"https://media.zenfs.com/en/globenewswire.com/3f8437bbc260e242d30bfffaf8d5061a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BsGI1WctFPXwRBa2KW_Skg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3f8437bbc260e242d30bfffaf8d5061a","width":960,"height":960},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oTcVMcIy_CwMgz2WXVFdsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yNDAyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3f8437bbc260e242d30bfffaf8d5061a","width":1200,"height":1201}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.","length":406,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes,” said Thomas Zindrick, President, CEO, and Chairman of the Board. “He brings extensive experience in oncology drug development of innovative therapies, including a proven track record of leading complex programs from early development through late-stage trials. Jason’s insight and disciplined approach to clinical execution will support our momentum as we approach key readouts in ovarian and lung cancer and work to unlock t...